ADAR1 Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

ADAR1 Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.33M	Buy	133,000 +28,000	+27%	+$253K	0.06%	155
2026 Q1	$1,000K	Buy	105,000 +60,000	+133%	+$466K	0.06%	163
2025 Q4	$351K	Buy	+45,000	New	+$325K	0.03%	203
2025 Q2	–	Sell	-10,000	Closed	-$75K	–	213
2025 Q1	$75K	Sell	10,000 -25,000	-71%	-$202K	0.01%	173
2024 Q4	$263K	Hold	35,000	–	–	0.05%	146
2024 Q3	$266K	Buy	35,000 +5,600	+19%	+$42.6K	0.04%	149
2024 Q2	$182K	Buy	+29,400	New	+$162K	0.03%	147

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

ADAR1 Capital Management's BCRX Position: Q2 2026 in Review

ADAR1 Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 27% in Q2 2026, buying an estimated $253K and bringing the position to 133,000 shares worth $1.33M. The position accounts for 0.06% of the portfolio, ranked #155.

ADAR1 Capital Management first reported a position in BCRX in Q2 2024 and has held it in 7 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

ADAR1 Capital Management held 133,000 shares of BioCryst Pharmaceuticals worth $1.33M as of Q2 2026.
ADAR1 Capital Management bought 28,000 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $253K.
BioCryst Pharmaceuticals made up 0.06% of ADAR1 Capital Management's portfolio in Q2 2026, its #155 holding.
ADAR1 Capital Management first reported a position in BioCryst Pharmaceuticals in Q2 2024 and has held it in 7 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.